Meira Abramowitz
Gastroenterology · New York, NYNPI 1114151370
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 33.1% of the total. 2025 is the largest year on record at $351, 2.0 times the $173 reported in 2023. That places this record below the midpoint for gastroenterology clinicians in NY, where the typical reported total is $1,827.
Across 28 payments — averaging $26.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$243
- Pfizer$198
- Boehringer Ingelheim$125
- Lilly USA, LLC$54
- Takeda Pharmaceuticals U.S.A., Inc.$54
- Ardelyx, Inc.$45
- plus $15 from 1 others
Across 2 payments — averaging $10,663 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$21K
What the payments were for
- Food & beverage$734100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 9 | $243 |
| Pfizer | 10 | $198 |
| Boehringer Ingelheim | 1 | $125 |
| Lilly USA, LLC | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Ardelyx, Inc. | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$734 in reported general payments places this provider in the 30th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 11 | $1,922 |
| Omeprazole | 40 | $495 |
| Famotidine | 13 | $131 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in New York
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
- Caterina Oneto ArayaNew York$610K
- Dana LukinNew York$491K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.